{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:05:25Z","timestamp":1789725925446,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.kint.2026.05.024","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:22:40Z","timestamp":1783416160000},"page":"807-811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complement inhibition in Shiga toxin\u2013producing Escherichia coli\u2013associated hemolytic uremic syndrome: rationale versus evidence"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4242-3154","authenticated-orcid":false,"given":"Alison Lap-tak","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily E.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-6005","authenticated-orcid":false,"given":"Eugene Yu-hin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.05.024_bib1","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104: H4 induced haemolytic\u2013uraemic syndrome: an analysis of the German STEC-HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.05.024_bib2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0022-3476(97)70050-7","article-title":"Hemolytic uremic syndrome: presence or absence of diarrheal prodromes","volume":"131","author":"Pire","year":"1997","journal-title":"J Pediatr"},{"key":"10.1016\/j.kint.2026.05.024_bib3","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00467-018-3991-6","article-title":"Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome","volume":"33","author":"Alconcher","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.05.024_bib4","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3201\/eid2707.204638","article-title":"Shiga toxin\u2013associated hemolytic uremic syndrome in adults, France, 2009\u20132017","volume":"27","author":"Travert","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.kint.2026.05.024_bib5","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.290.10.1360","article-title":"Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression","volume":"290","author":"Garg","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2026.05.024_bib6","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1007\/s00467-024-06355-z","article-title":"Outcome 10 years after Shiga toxin-producing E. coli (STEC)-associated hemolytic uremic syndrome: importance of long-term follow-up","volume":"39","author":"Rosales","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.05.024_bib7","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/cid\/cix218","article-title":"Intermediate follow-up of pediatric patients with hemolytic uremic syndrome during the 2011 outbreak caused by E. coli O104: H4","volume":"64","author":"Loos","year":"2017","journal-title":"Clin InfectDis"},{"key":"10.1016\/j.kint.2026.05.024_bib8","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMra2108739","article-title":"Shiga toxin\u2013producing Escherichia coli and the hemolytic\u2013uremic syndrome","volume":"389","author":"Freedman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.05.024_bib9","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(73)92782-7","article-title":"Serum-complement levels in haemolytic-uraemic syndrome","volume":"302","author":"Kaplan","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2026.05.024_bib10","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.2215\/CJN.02730409","article-title":"Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome","volume":"4","author":"Thurman","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.05.024_bib11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.medj.2023.09.002","article-title":"Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation","volume":"4","author":"Bowen","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.kint.2026.05.024_bib12","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.kint.2026.05.025","article-title":"Why current evidence does not support routine C5 inhibition in Shiga toxin\u2013producing Escherichia coli\u2013associated hemolytic uremic syndrome","volume":"110","author":"Loos","year":"2026","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.05.024_bib13","first-page":"799","article-title":"A rationale for C5 inhibition in severe Shiga toxin\u2013producing Escherichia coli\u2013associated hemolytic uremic syndrome","volume":"110","author":"Coccia","year":"2026","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.05.024_bib14","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1681\/ASN.0000000000000182","article-title":"Efficacy and safety of eculizumab in pediatric patients affected by Shiga toxin\u2013related hemolytic and uremic syndrome: a randomized, placebo-controlled trial","volume":"34","author":"Garnier","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.05.024_bib16","unstructured":"Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU (ECULISHU). ClinicalTrials.gov Identifier: NCT02205541. Updated May 4, 2026. Accessed July 16, 2026. https:\/\/clinicaltrials.gov\/study\/NCT02205541"},{"key":"10.1016\/j.kint.2026.05.024_bib15","first-page":"1","article-title":"Efficacy and safety of eculizumab in children with Shiga-toxin-producing Escherichia coli haemolytic uraemic syndrome: the ECUSTEC RCT","volume":"11","author":"Ives","year":"2024","journal-title":"Efficacy Mechanism Eval"},{"key":"10.1016\/j.kint.2026.05.024_bib17","unstructured":"Eculizumab in Shiga-Toxin producing E. Coli Haemolytic Uraemic Syndrome (ECUSTEC): A Randomised, Double-Blind, Placebo-Controlled Trial. EudraCT number: 2016-000997-39. Updated November 25, 2021. Accessed July 30, 2026. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-000997-39\/results"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525382600517X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525382600517X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:30:47Z","timestamp":1789723847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525382600517X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S008525382600517X"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.05.024","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement inhibition in Shiga toxin\u2013producing Escherichia coli\u2013associated hemolytic uremic syndrome: rationale versus evidence","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.05.025","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.04.042","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}